The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
Quiz|Articles|October 22, 2023
- Dermatology Times, November 2023 (Vol. 44. No. 11)
- Volume 44
- Issue 11
QUIZ: Which of the Following Conditions is NOT a Mimicker of Melasma?
Author(s)Kaitlyn Bader, Senior Editor
Susan Taylor, MD, walked Fall Clinical attendees through an in-depth hyperpigmentation session that included melasma and its mimickers.
Advertisement
Which of the following conditions is NOT a mimicker of melasma?
Articles in this issue
almost 3 years ago
Discovering Dermatology Times: November 2023almost 3 years ago
I Was in a Hurry, and I Was Suedalmost 3 years ago
AD Case Study: Topical Steroids Are Not Cutting Italmost 3 years ago
Why Dermatologists Are Not Average Investorsalmost 3 years ago
New International Vitiligo Task Force Recommendationsalmost 3 years ago
Navigating the Complexities of Atopic Dermatitisalmost 3 years ago
Investigating Links Between Cancer and Psoriasis Managementalmost 3 years ago
Key Considerations for Optimal Atopic Dermatitis Care Across All Agesalmost 3 years ago
Understanding Topical Growth Factors and Skin RejuvenationAdvertisement
Related to this article
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis
2
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
3
FDA Revises TB Evaluation Guidance for SKYRIZI
4
Avoiding Common Mistakes When Escalating Therapy in Psoriasis
5